DDInter948 DDInter1619
Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD
Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label], . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome . In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole .
Ropinirole {u} (Compound) binds {v} (Gene) DRD1
Ropinirole {u} (Compound) upregulates {v} (Gene) GHR
Ropinirole {u} (Compound) palliates {v} (Disease) Alzheimer's disease
Ropinirole {u} (Compound) downregulates {v} (Gene) STXBP2
Ropinirole {u} (Compound) causes {v} (Side Effect) Breast cyst
Ropinirole (Compound) binds DRD1 (Gene)
Ropinirole (Compound) upregulates GHR (Gene)
Ropinirole (Compound) palliates Alzheimer's disease (Disease)
Ropinirole (Compound) downregulates STXBP2 (Gene)
Ropinirole (Compound) causes Breast cyst (Side Effect)